Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 809 across all filing types
Latest filing 2025-11-10 Director's Dealing
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Comunicato Internal Dealing
Director's Dealing Classification · 100% confidence The document is a formal notification of 'Internal Dealing' (insider trading) regarding transactions conducted by a person discharging managerial responsibilities (PDMR). It uses the standard EU Market Abuse Regulation (MAR) template for the notification and public disclosure of transactions by persons discharging managerial responsibilities. This matches the definition for 'Director's Dealing' (DIRS).
2025-11-10 Italian
Diasorin 9M 2025 Results Presentation
Investor Presentation Classification · 100% confidence The document is a detailed slide deck titled 'Q3 & 9M 2025 RESULTS' for Diasorin S.p.A. It contains financial performance metrics, revenue variances, business segment updates (Immunodiagnostics, Molecular Diagnostics), and forward-looking statements. It is clearly an investor-facing presentation used to communicate quarterly results, which fits the definition of an Investor Presentation (IP).
2025-11-05 English
Diasorin’s Board of Directors approves results for the first 9 months of 2025. FY 2025 Guidance revised
Earnings Release Classification · 100% confidence The document is a press release from Diasorin S.p.A. announcing its financial results for the first 9 months of 2025. It includes key performance indicators (revenues, EBITDA, EBIT, net profit), business highlights, and a revised FY 2025 guidance. It is clearly an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). 9M 2025
2025-11-05 English
Il Consiglio di Amministrazione di Diasorin approva i risultati dei primi 9 mesi del 2025. Rivista la Guidance per l’esercizio 2025
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Diasorin S.p.A. announcing its financial results for the first 9 months of 2025. It contains detailed financial tables (Revenue, EBITDA, EBIT, Net Income) and a management commentary explaining the performance, business segments, and geographic results. It is not a full annual report (10-K) nor a mere announcement of a report (RPA), but rather the primary release of quarterly financial data. Therefore, it is classified as an Interim/Quarterly Report (IR). 9M 2025
2025-11-05 Italian
Communication on total amount of voting rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal communication regarding the total amount of voting rights, specifically referencing Article 85-bis of the CONSOB Regulation. It details changes in voting rights due to the assignment and waiver of increased voting rights by shareholders. This type of regulatory disclosure regarding share capital and voting rights structure is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like 'Major Shareholding Notification' (which usually refers to crossing thresholds) or 'Declaration of Voting Results' (which refers to meeting outcomes).
2025-10-07 English
Comunicazione dell'ammontare complessivo dei diritti di voto
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal communication from Diasorin S.p.A. regarding the total amount of voting rights, specifically referencing Art. 85-bis, paragraph 4-bis of the CONSOB Regulation. It details changes in voting rights due to shareholders acquiring or renouncing 'voto maggiorato' (loyalty shares). While this relates to share capital structure, it is specifically a disclosure of voting rights and share composition, which falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-10-07 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.